Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRIW) Revenue (2020 - 2025)

Biofrontera has reported Revenue over the past 6 years, most recently at $17.1 million for Q4 2025.

  • Quarterly results put Revenue at $17.1 million for Q4 2025, up 36.16% from a year ago — trailing twelve months through Dec 2025 was $41.7 million (up 11.75% YoY), and the annual figure for FY2025 was $41.7 million, up 11.75%.
  • Revenue for Q4 2025 was $17.1 million at Biofrontera, up from $7.0 million in the prior quarter.
  • Over the last five years, Revenue for BFRIW hit a ceiling of $17.1 million in Q4 2025 and a floor of $4.3 million in Q3 2022.
  • Median Revenue over the past 5 years was $8.7 million (2023), compared with a mean of $8.3 million.
  • Biggest five-year swings in Revenue: decreased 23.88% in 2022 and later soared 105.83% in 2023.
  • Biofrontera's Revenue stood at $9.2 million in 2021, then rose by 10.65% to $10.1 million in 2022, then rose by 4.46% to $10.6 million in 2023, then grew by 18.53% to $12.6 million in 2024, then surged by 36.16% to $17.1 million in 2025.
  • The last three reported values for Revenue were $17.1 million (Q4 2025), $7.0 million (Q3 2025), and $9.0 million (Q2 2025) per Business Quant data.